JP2005511019A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511019A5 JP2005511019A5 JP2003528849A JP2003528849A JP2005511019A5 JP 2005511019 A5 JP2005511019 A5 JP 2005511019A5 JP 2003528849 A JP2003528849 A JP 2003528849A JP 2003528849 A JP2003528849 A JP 2003528849A JP 2005511019 A5 JP2005511019 A5 JP 2005511019A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- gag
- nef
- protein
- codon optimized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 19
- 125000003729 nucleotide group Chemical group 0.000 claims 19
- 108020004705 Codon Proteins 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 239000013598 vector Substances 0.000 claims 6
- 101710177291 Gag polyprotein Proteins 0.000 claims 5
- 101710125418 Major capsid protein Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 108700010070 Codon Usage Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 101150102264 IE gene Proteins 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 101710145242 Minor capsid protein P3-RTD Proteins 0.000 claims 1
- 101710192141 Protein Nef Proteins 0.000 claims 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2001/004207 WO2002024225A1 (en) | 2000-09-20 | 2001-09-20 | Use of immidazoquinolinamines as adjuvants in dna vaccination |
| GB0129604A GB0129604D0 (en) | 2001-12-11 | 2001-12-11 | Novel compounds |
| GB0206462A GB0206462D0 (en) | 2002-03-19 | 2002-03-19 | Vaccines |
| PCT/EP2002/010592 WO2003025003A2 (en) | 2001-09-20 | 2002-09-18 | Hiv-gag codon-optimised dna vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005511019A JP2005511019A (ja) | 2005-04-28 |
| JP2005511019A5 true JP2005511019A5 (enExample) | 2006-01-05 |
| JP4601956B2 JP4601956B2 (ja) | 2010-12-22 |
Family
ID=27256076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003528849A Expired - Fee Related JP4601956B2 (ja) | 2001-09-20 | 2002-09-18 | Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20070015721A1 (enExample) |
| EP (2) | EP1427826B1 (enExample) |
| JP (1) | JP4601956B2 (enExample) |
| CN (1) | CN100392085C (enExample) |
| AR (1) | AR036566A1 (enExample) |
| AU (1) | AU2002362368B2 (enExample) |
| BR (1) | BR0212619A (enExample) |
| CA (1) | CA2461056A1 (enExample) |
| CO (1) | CO5560591A2 (enExample) |
| HU (1) | HUP0402259A3 (enExample) |
| IL (1) | IL160809A0 (enExample) |
| MX (1) | MXPA04002631A (enExample) |
| NO (1) | NO331826B1 (enExample) |
| NZ (1) | NZ531814A (enExample) |
| PL (1) | PL207168B1 (enExample) |
| WO (1) | WO2003025003A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050266024A1 (en) * | 2002-03-19 | 2005-12-01 | Powdermed Limited | Adjuvant |
| GB0225788D0 (en) | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
| GB2406336A (en) * | 2003-09-24 | 2005-03-30 | Oxxon Pharmaccines Ltd | HIV Pharmaccines |
| GB0417494D0 (en) * | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| DE102004049223A1 (de) * | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
| AU2012201827B2 (en) * | 2005-05-12 | 2014-09-04 | Glaxo Group Limited | Vaccine composition |
| BRPI0608798A2 (pt) * | 2005-05-12 | 2011-03-15 | Glaxo Group Ltd | vetor de adenovìrus, composição imunogênica, uso de um vetor de adenovìrus, método para preparar um vetor, uso de um vetor de vìrus e um carreador ou adjuvante farmaceuticamente aceitável, e, proteìna de fusão |
| WO2008133663A2 (en) * | 2006-11-30 | 2008-11-06 | Government Of The United States Of America, As Represented By The Secretary, | Codon modified immunogenic compositions and methods of use |
| GB0700914D0 (en) * | 2007-01-18 | 2007-02-28 | Animal Health Inst | Polynucleotides and uses thereof |
| CN103550764A (zh) | 2007-03-02 | 2014-02-05 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物及其在刺激免疫反应中的用途 |
| CN101678091A (zh) | 2007-05-24 | 2010-03-24 | 葛兰素史密丝克莱恩生物有限公司 | 冷冻干燥的抗原组合物 |
| WO2009092113A2 (en) * | 2008-01-19 | 2009-07-23 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the delivery of vaccines to disrupted epithelium |
| WO2011043830A2 (en) * | 2009-10-09 | 2011-04-14 | New York University | Methods, agents and peptides for inducing an innate immune response in hiv vaccination |
| BRPI0914507A2 (pt) * | 2009-12-23 | 2012-04-10 | Fundacao Oswaldo Cruz | vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela |
| WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| PT3351636T (pt) * | 2010-05-14 | 2020-09-24 | Univ Oregon Health & Science | Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos |
| GB201022007D0 (en) | 2010-12-24 | 2011-02-02 | Imp Innovations Ltd | DNA-sensor |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| LT2964769T (lt) | 2013-03-05 | 2018-12-10 | Oregon Health & Science University | Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| NZ728208A (en) | 2014-07-16 | 2018-07-27 | Univ Oregon Health & Science | Human cytomegalovirus comprising exogenous antigens |
| MA40783A (fr) * | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| EA201791806A1 (ru) | 2015-02-10 | 2017-12-29 | Орегон Хелс Энд Сайенс Юниверсити | Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| US10688164B2 (en) | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| WO2018075591A1 (en) | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
| CN113924114A (zh) | 2019-05-22 | 2022-01-11 | 吉利德科学公司 | Tlr7调节化合物和hiv疫苗的组合 |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| EP0500799B1 (en) | 1989-11-16 | 1998-01-14 | Duke University | Particle mediated transformation of animal skin tissue cells |
| US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5583035A (en) * | 1992-12-07 | 1996-12-10 | Bayer Aktiengesellschaft | HIV antisense expression vectors |
| US5654186A (en) | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
| WO1995019799A1 (en) | 1994-01-21 | 1995-07-27 | Agracetus, Inc. | Gas driven gene delivery instrument |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US5786464C1 (en) * | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| ATE309366T1 (de) * | 1996-02-22 | 2005-11-15 | Merck & Co Inc | Synthetische hiv-gene |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| JP2001513643A (ja) * | 1997-03-06 | 2001-09-04 | ウーベルラ、クラウス | レンチウイルスをベースとするベクター及びベクター系 |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| EP1141314A2 (en) * | 1998-12-31 | 2001-10-10 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| AU2221600A (en) * | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| CN1423698A (zh) * | 1999-11-16 | 2003-06-11 | 真那特应用生物科技有限公司 | Hiv－1亚型间(c/b’)基因组和其用途 |
| AU782193B2 (en) * | 1999-12-17 | 2005-07-07 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef |
| US6656706B2 (en) * | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
| DK1240186T3 (da) * | 1999-12-23 | 2010-05-31 | Medical Res Council | Forbedringer i eller relateret til immunrespons mod HIV |
| ATE318908T1 (de) * | 2000-05-18 | 2006-03-15 | Geneart Gmbh | Synthetische gene für gagpol und deren verwendungen |
| EP2302059A1 (en) * | 2000-08-14 | 2011-03-30 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization |
-
2002
- 2002-09-18 JP JP2003528849A patent/JP4601956B2/ja not_active Expired - Fee Related
- 2002-09-18 WO PCT/EP2002/010592 patent/WO2003025003A2/en not_active Ceased
- 2002-09-18 CA CA002461056A patent/CA2461056A1/en not_active Abandoned
- 2002-09-18 IL IL16080902A patent/IL160809A0/xx unknown
- 2002-09-18 MX MXPA04002631A patent/MXPA04002631A/es active IP Right Grant
- 2002-09-18 EP EP02798748A patent/EP1427826B1/en not_active Expired - Lifetime
- 2002-09-18 HU HU0402259A patent/HUP0402259A3/hu unknown
- 2002-09-18 BR BR0212619-2A patent/BR0212619A/pt not_active IP Right Cessation
- 2002-09-18 AU AU2002362368A patent/AU2002362368B2/en not_active Ceased
- 2002-09-18 NZ NZ531814A patent/NZ531814A/en not_active IP Right Cessation
- 2002-09-18 US US10/490,011 patent/US20070015721A1/en not_active Abandoned
- 2002-09-18 EP EP10180900A patent/EP2322626A1/en not_active Ceased
- 2002-09-18 CN CNB028230876A patent/CN100392085C/zh not_active Expired - Fee Related
- 2002-09-18 PL PL370359A patent/PL207168B1/pl not_active IP Right Cessation
- 2002-09-20 AR ARP020103561A patent/AR036566A1/es active IP Right Grant
-
2004
- 2004-03-17 CO CO04025208A patent/CO5560591A2/es not_active Application Discontinuation
- 2004-03-19 NO NO20041157A patent/NO331826B1/no not_active IP Right Cessation
-
2008
- 2008-01-17 US US12/015,756 patent/US20090203144A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Epstein et al. | HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies | |
| Kozlovska et al. | RNA phage Qβ coat protein as a carrier for foreign epitopes | |
| US8389275B2 (en) | Fusion proteins of HIV regulatory/accessory proteins | |
| CN115529817A (zh) | 疫苗及其诱导针对sars-cov2的免疫应答的用途 | |
| JP2023512519A5 (enExample) | ||
| RU2012107671A (ru) | Композиция для лечения инфекции вирусом гепатита в | |
| US20210100891A1 (en) | Compositions and Methods for Generating an Immune Response to a Flavivirus | |
| JP2014527404A5 (enExample) | ||
| CN101484466A (zh) | 针对流感病毒的抗病毒剂和疫苗 | |
| US20200171141A1 (en) | Compositions and Methods for Generating an Immune Response to LASV | |
| NO331826B1 (no) | Nukleotidsekvens, vektor, protein, farmasoytisk preparat, intradermal avleveringsanordning, samt fremgangsmate for fremstilling av en nukleotidsekvens. | |
| ES2303513T3 (es) | Genoma del intersubtipo (c/b') de vih-1 y sus aplicaciones. | |
| TW202118771A (zh) | 疫苗 | |
| CN1100564C (zh) | 用于治疗hiv感染的药物、其组合物及其用途 | |
| CN1173897A (zh) | 真核起始因子5A(eIF－5A)突变体 | |
| JP2005502339A5 (enExample) | ||
| RU2004107853A (ru) | Вич-gag днк вакцины, оптимизированные по кодонам | |
| Turner et al. | Variability in the PR and RT genes of HIV-1 isolated from recently infected subjects | |
| JP2025501550A (ja) | 偽型化レンチウイルスベクター | |
| WALKER | HIV Vaccines 2000: Prospects and Challenges | |
| Dwivedi et al. | Anti-HIV therapy: pipeline approaches and future directions | |
| CN1570101A (zh) | 优化的sars冠状病毒n蛋白基因 | |
| JPH11239486A (ja) | 組み換え型ヒト免疫不全ウイルス１型ウイルス、並びに、その産生に用いるウイルス分子クローン | |
| HK1046428B (en) | The genome of the hiv-1 inter-subtype (c/b') and use thereof | |
| HK1083192A1 (en) | West nile virus vaccine |